Bioneer Corporation (064550) Fair Value & Analysis
Healthcare · KR · Market cap 160B KRW
Fair value as of: Jul 22, 2026
From 12 valuation models · updated 18 days ago
Share price +6.8% over the past month.
A solid business, screening 20% undervalued on our models.
What matters now
- Solid quality (58/100) at a price below fair value, the discount is the argument here, not the business quality.
- A fairly wide model range (4,809 KRW to 11,032 KRW) leaves room in how you read the outcome.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 22, 2026.
How to read this chart
60‑month range 5,790 KRW – 93,200 KRW · fair‑value band 4,809 KRW – 11,032 KRW · the 6,910 KRW price screens below the 8,312 KRW fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 22, 2026.
Analysis
Bioneer Corporation (064550) currently trades at 6,910 KRW, while our model-based Fair Value estimate is 8,312 KRW, implying the stock looks roughly 20.3% undervalued today. The Quality Score stands at 58/100 (solid quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium), always confirm before acting.
Over the trailing twelve months, Bioneer Corporation generated revenue of 224B KRW at a net margin of 10.3%. Revenue declined 14.7% year over year. Net debt stands at 56.8B KRW. Fundamentals as of Jul 22, 2026
Our scenario range runs from 4,809 KRW (bear case) to 11,032 KRW (bull case); at 6,910 KRW, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 60% below its 52-week high, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -20% fair-value upside, at 20%, 064550 screens cheaper than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 12 models by family
Widest divergence: DCF Models (11,329 KRW) versus Earnings-Based (2,991 KRW). Highest evidence: Growth DCF (80).
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 22, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 53 · Market factors (momentum, volatility) 19
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea.
Full company description
Bioneer Corporation engages in the biotechnology research products, molecular diagnosis, drugs, and probiotics businesses in South Korea. The company offers PCR and RT-PCR, real-time PCR, RNAi, chemicals, plastic consumables, and buffer solutions; and sample preparation, protein synthesis and purification, gene cloning, fluorescence dye and quencher, electrophoresis, genome-wide functional analysis, and magnetic separation services, as well as instruments for conventional PCR, real-time PCR, sample preparation, protein synthesis, centrifuge and vortex mixer, electrophoresis, spectrophotometer, and microbial culture. It also provides molecular diagnosis, including MDx technologies, human diagnostics kits, MDx extraction kits, and instruments; and products for animal diseases and nano-bio products. The company was founded in 1992 and is headquartered in Daejeon, South Korea.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Bioneer Corporation reported revenue of 330B KRW in FY2025 versus 224B KRW in FY2021, a compound +10.2%/yr. Reported net income was −2.8B KRW in FY2025.
Watch 064550: get an alert when its fair value changes →
Peer Group
Health Care · 2228 stocks
How this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)
Valuation Multiples vs Health Care median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate (as of Jul 22, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| MEDIPOST Co 078160 | 8,150 KRW | 4,269 KRW | -48% |
| Macrogen, Inc 038290 | 11,090 KRW | 4,457 KRW | -60% |
| Cell Biotech Co 049960 | 14,980 KRW | 19,433 KRW | +30% |
| Panagene Inc 046210 | 1,068 KRW | 480.36 KRW | -55% |
| Biotoxtech Co 086040 | 2,010 KRW | 1,481 KRW | -26% |
| Novartis AG NVSN | 2,742 MXN | 2,379 MXN | -13% |
| Sanofi SNYN | 770.00 MXN | 1,251 MXN | +63% |
| GSK plc GSKN | 917.00 MXN | 1,078 MXN | +18% |
| Sun Pharmaceutical Industries Limited SUNPHARMA | ₹1,933 | ₹989.50 | -49% |
| Samsung Biologics Co 207940 | 1,368,000 KRW | 1,091,384 KRW | -20% |
Compare Bioneer Corporation with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Bioneer Corporation (064550) overvalued or undervalued?
What is the fair value of 064550?
What is the quality score of 064550?
What is the revenue of Bioneer Corporation (064550)?
What is the net profit margin of 064550?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Bioneer Corporation and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.